01/08/2021

LumiraDx Receives SARS-CoV-2 Antigen Examination Authorization in Japan and Brazil Italy Recommends Growth of Microfluidic Antigen Testing

LONDON, Jan. 21, 2021 /PRNewswire/ — LumiraDx, the next-technology stage-of-care diagnostic testing business, declared right now multinational approvals of its SARS-CoV-2 Antigen Check. With approvals in Japan and Brazil, the quick, exact LumiraDx SARS-CoV-2 Antigen Check is now offered to sufferers in much more than 30 nations around the globe. In addition to these authorizations, the Italian Affiliation for Clinical Microbiology not long ago posted screening pointers favorable to future-generation microfluidic technological innovation – like LumiraDx’s – for COVID-19 testing.

The LumiraDx SARS-CoV-2 Antigen Test is a microfluidic immunofluorescence assay developed to detect SARS-CoV-2 antigen in nasal or nasopharyngeal swab specimens, with superior sensitivity effects in 12 minutes from sample application.

On January 19th, LumiraDx grew to become the 1st foreign business to obtain approval for its SARS-CoV-2 Antigen Take a look at from Japan’s Pharmaceutical and Clinical Units Company (PMDA). On January 18th, The Brazilian Wellbeing Regulatory Agency, or ANVISA (Agência Nacional de Vigilância Sanitária), issued approval for the LumiraDx SARS-CoV-2 Antigen Check. In get to reach authorization, LumiraDx performed a number of reports and underwent an audit by the regulatory authorities. The enterprise options to launch shortly in both of those Japan and Brazil, originally providing its antigen test to hospitals to support with the recent immediate COVID-19 unfold.

In more validation of the strengths of the LumiraDx SARS-CoV-2 Antigen Examination, the Italian Affiliation for Clinical Microbiology (AMCLI-IT) posted new pointers on January 4th encouraging use of microfluidic technology. AMCLI-IT located “antigenic tests with fluorescence looking through have much better overall performance (as opposed to other antigenic assessments) and particularly these of a lot more modern introduction (immunofluorescence with microfluidic reading) seem to be to clearly show success superimposable to those people of the serious-time RT-PCR assay.” Centered on the AMCLI-IT place, the Italian Ministry of Wellness said that microfluidic antigen checks with fluorescence reading through look to be a valid choice to RT-PCR, and as opposed to lateral move assessments, do not involve affirmation of a positive result with RT-PCR and could even serve as an option confirmatory check to RT-PCR.*

The LumiraDx SARS-CoV-2 Antigen Take a look at is at this time commercially out there in the US, Europe, Middle East, Africa and Asia Pacific. The LumiraDx Platform – comprised of a modest, transportable instrument microfluidic test strip and safe cloud-centered connectivity – presents quick, accurate diagnostic take a look at effects to individuals in group care options.

The LumiraDx SARS-CoV-2 Antigen Check is approved for use by Fda below an Crisis Use Authorization (EUA) only for the detection of SARS-CoV-2 nucleocapsid protein. It has not been licensed for use to detect any other viruses or pathogens. The LumiraDx SARS-CoV-2 Antigen Take a look at is approved in the United States for the length of the declaration that conditions exist justifying the authorization of unexpected emergency use of in vitro diagnostic exams for detection and/or prognosis of COVID-19 beneath Portion 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), except the authorization is terminated or revoked faster.

*If the medical conditions of the patient show discrepancies with the microfluidic antigen check with fluorescence looking through, RT-PCR stays the gold conventional for the affirmation of Covid-19.

About LumiraDx
LumiraDx was launched in 2014 by a group of business owners: Ron Zwanziger, our Chairman and Main Government Officer Dave Scott, Ph.D., our Chief Know-how Officer and Jerry McAleer, Ph.D., our Chief Scientist, who have a thriving monitor record in setting up and scaling diagnostics organizations more than three a long time, which include at providers this kind of as Medisense, Inc., Inverness Health care Technology Inc. and Alere Inc. The firm is supported by institutional and strategic traders like the Monthly bill & Melinda Gates Foundation, Morningside Ventures, U.S. Boston Capital Company, and Petrichor Health care Funds Management. Dependent in the United kingdom and supported by its throughout the world affiliates to supply access in all key marketplaces, LumiraDx has around 1000 workforce around the globe.

LumiraDx develops, manufactures and commercializes an revolutionary level-of-treatment diagnostic System. The LumiraDx Platform is intended to deliver lab similar diagnostic effects at the place of care in minutes. It is made to be cost-effective and obtainable for health care suppliers globally, and to strengthen community-based healthcare.

Further data on LumiraDx and the LumiraDx System is offered at lumiradx.com.

View authentic written content to download multimedia: http://www.prnewswire.com/news-releases/lumiradx-receives-sars-cov-2-antigen-examination-authorization-in-japan-and-brazil-italy-recommends-expansion-of-microfluidic-antigen-testing-301212106.html

Supply LumiraDx